



## VF001002 CLINICAL TRIAL UPDATE: Strong May Performance Assures Study Completion On Track

**Brisbane**, **Australia 14th June 2018**: Factor Therapeutics Limited (ASX: FTT, the "Company"), an Australian biomedical company developing therapeutics for advanced wound care, is pleased to confirm excellent recruitment and screening during May in the company's Phase 2 clinical trial, VF00102.

"It's extremely pleasing to see how our sites have continued to push through this final period. May's performance was as strong as our previous best month, with 19 patients screened and 15 enrolled into the study," said Dr Ros Wilson, CEO of Factor Therapeutics. "The early indicators for June are just as positive and we are now at the point where we are closely monitoring the influx of patients to determine when to close screening."

Dr Wilson added, "This month's recruitment has been outstanding – and we're delighted that the trial readout is now only a few months away. Having the results in hand means we will be able to accelerate discussions with potential partners while we finalise our next steps with the EU and US regulatory authorities."





-ENDS-

## **Contact for Further Information:**

Dr. Rosalind Wilson
Chief Executive Officer
Factor Therapeutics Limited
r.wilson@factor-therapeutics.com

## **About Factor Therapeutics**

Factor Therapeutics Limited ("Factor") is a biomedical technology company that is developing treatments for acute and chronic wound healing applications. Factor is a clinical stage company with its lead program (VF-001) in Phase II for the treatment of venous leg ulcers (VLUs). The company is also developing solutions for a variety of interventional wound care and serious orphan dermatology conditions. The company's platform technology originates from the Institute of Health and Biomedical Innovation at the Queensland University of Technology (QUT), Australia. Factor's shares are traded on the Australian Securities Exchange (ASX) under the ticker FTT. For more information, please visit <a href="https://factor-therapeutics.com">https://factor-therapeutics.com</a>